Mirvetuximab ELISA Kit

Catalog No.

KDD10402

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

0.31-5 μg/mL

Sensitivity

0.156 μg/ml

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

M9346A, IMGN853, M9346A-sulfo-SPDB-DM4, CAS: 1453084-36-0

Background

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells.

Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker., PMID:40508029

Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters., PMID:40501953

Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer., PMID:40501444

State of the Art: Therapies Now and Around the Corner for Gynecologic Cancers., PMID:40489723

Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758

Ovarian Cancer Therapy., PMID:40389314

Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer., PMID:40270982

Monotherapy and combination therapy using antibody‑drug conjugates for platinum‑resistant ovarian cancer., PMID:40242965

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial., PMID:40179908

FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma., PMID:40150910

Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics., PMID:40139025

A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer., PMID:40126684

Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate., PMID:40121972

Addressing the challenge of platinum-resistant ovarian cancer: the role of mirvetuximab soravtansine., PMID:40109581

Mirvetuximab soravtansine: current and future applications., PMID:40102896

Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report., PMID:40050918

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial., PMID:40044930

Gastrointestinal toxicity of antibody-drug conjugates: a pharmacovigilance study using the FAERS database., PMID:40033454

IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer., PMID:40029935

Intraepithelial corneal deposits associated with Mirvetuximab soravtansine use for platinum-resistant ovarian cancer., PMID:40028469

[Mirvetuximab soravtansine as monotherapy in platinum-resistant ovarian cancer expressing alpha folate receptor]., PMID:40016053

Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells., PMID:39996761

Mirvetuximab soravtansine shines post-PARP inhibitor progression: promising insights from the PICCOLO trial., PMID:39988550

Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies., PMID:39970828

A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective., PMID:39922351

Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines., PMID:39900344

Development of an FRα Companion Diagnostic Immunohistochemical Assay for Mirvetuximab Soravtansine., PMID:39734248

Mirvetuximab Soravtansine in solid tumors: A systematic review and meta-analysis., PMID:39729462

Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know., PMID:39641680

Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy., PMID:39640287

Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers., PMID:39631181

The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial., PMID:39617145

Folate Receptor Alpha-A Secret Weapon in Ovarian Cancer Treatment?, PMID:39595996

Antibody-Drug Conjugates: A Start of a New Era in Gynecological Cancers., PMID:39590153

The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis., PMID:39526448

Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary., PMID:39461270

Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer., PMID:39378056

Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen., PMID:39307840

Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature., PMID:39281842

Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)., PMID:39228525

[Antibody-Drug Conjugates in Breast Cancer and Gynecologic Cancer]., PMID:39191683

Accuracy and Completeness of Large Language Models About Antibody-Drug Conjugates and Associated Ocular Adverse Effects., PMID:39110155

Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer., PMID:39082675

Mirvetuximab after anaphylaxis to Paclitaxel: A case report., PMID:39076678

Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer., PMID:39061184

Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities., PMID:38941962

Folate Receptor Immunohistochemical Staining and Gynecologic Tumors: Initial Experience With 216 Cases., PMID:38914019

Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial., PMID:38858103

Ocular toxicities associated with antibody drug conjugates., PMID:38814581

Comparison of target agent treatment strategies for platinum-resistant recurrent ovarian cancer: A Bayesian network meta-analysis., PMID:38788019

Document Download

Mirvetuximab ELISA Kit.pdf